文献速递关节外科

骨内万古霉素降低二期翻修TKA再植入后感染复发率

The John N. Insall Award: Reduced Reinfection Rate With Intraosseous Vancomycin Administration at Reimplantation in Two-Stage Revision Total Knee Arthroplasty.
PubMed 文献 · J Arthroplasty · 2026-04-01

这项回顾性队列研究纳入252例因感染行二期翻修全膝关节置换术的患者,比较再植入时骨内万古霉素(101例)与静脉抗生素预防(151例)的再感染率。骨内组1年、2年、3年再感染率均显著低于静脉组,未用骨内万古霉素者3年再感染风险近三倍。

要点

  • 再植入时骨内万古霉素组1年再感染率6% vs 14%(P=0.049)。
  • 2年再感染率9% vs 22%(P=0.025),3年16% vs 30%(P=0.045)。
  • 未用骨内万古霉素者3年再感染比值比2.9(P=0.025)。

核心结论

  • 二期翻修TKA再植入时骨内万古霉素较单纯静脉抗生素预防显著降低复发性假体周围感染率。

研究设计与样本

  • 单中心回顾性队列研究,纳入2016年7月至2025年3月因感染行二期翻修TKA的252例患者,骨内万古霉素组101例,静脉抗生素组151例。

主要发现

  • 骨内万古霉素组再感染率在1年(6% vs 14%,P=0.049)、2年(9% vs 22%,P=0.025)、3年(16% vs 30%,P=0.045)均显著低于静脉组。
  • 未接受骨内万古霉素者3年再感染比值比为2.9(P=0.025)。
  • 44例再感染中39例培养阳性,其中33例(85%)对万古霉素敏感。

关键数值与推荐

  • 骨内组方案为静脉头孢唑林联合骨内输注500 mg万古霉素;静脉组为静脉头孢唑林,根据术者偏好联合或不联合静脉万古霉素。
  • 两组平均年龄、体重指数和性别无显著差异;慢性感染占92%,最常见病原体为凝固酶阴性葡萄球菌(23%)和甲氧西林敏感金黄色葡萄球菌(17%)。

临床怎么用

  • 在二期翻修TKA再植入时,可考虑采用骨内万古霉素作为辅助预防措施以降低再感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent periprosthetic joint infection (PJI) after two-stage exchange total knee arthroplasty (TKA) is associated with increased morbidity and mortality. Intraosseous (IO) vancomycin has been shown to reduce PJI rates in primary and aseptic revision TKA, but its role in two-stage revision for infection remains unknown. This study aimed to compare reinfection rates following IO vancomycin versus intravenous (IV) antibiotic prophylaxis at the time of reimplantation. METHODS: We conducted a retrospective cohort study of 252 patients who underwent two-stage revision for infected TKA at a single institution between July 2016 and March 2025, of whom 101 received IO vancomycin and 151 received IV antibiotics. Patients in the IO group received IV cefazolin plus 500 mg of vancomycin via IO infusion, while those in the IV group received IV cefazolin with or without IV vancomycin, according to surgeon preference. There were no significant differences in average age, body mass index, or sex between the two groups. Most cases involved chronic infection (92%), with coagulase-negative staphylococci (23%) and methicillin-sensitive Staphylococcus aureus (17%) as the most common organisms. Reinfection rates were compared between groups. RESULTS: Reinfection rates were significantly lower in the IO vancomycin group at one year (6 versus 14%, P = 0.049), two years (9 versus 22%, P = 0.025), and three years (16 versus 30%, P = 0.045) after reimplantation. Logistic regression analyses showed that patients who did not receive IO vancomycin at reimplantation had a nearly threefold increased odds of reinfection at three years (odds ratio 2.9, P = 0.025). Of the 44 reinfections, 39 yielded a positive culture, 33 of 39 (85%) of which were sensitive to vancomycin. CONCLUSIONS: Intraosseous vancomycin administration at the time of reimplantation during two-stage revision TKA was associated with significantly reduced rates of recurrent PJI compared to IV antibiotic prophylaxis alone.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Liu JW, McNamara CA, Sullivan TC, et al. The John N. Insall Award: Reduced Reinfection Rate With Intraosseous Vancomycin Administration at Reimplantation in Two-Stage Revision Total Knee Arthroplasty. J Arthroplasty. 2026. PMID: 41934051. doi:10.1016/j.arth.2026.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。